How AFib is treated: the three separate jobs
Last reviewed November 17, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
AFib treatment looks complicated because three independent decisions are being made at once, often in the same appointment, with medicines that sound similar.
Separating them makes the plan legible: one decision is about the brain, one is about the heart rate, and one is about the rhythm itself.
Related pages: Atrial fibrillation (AFib)
The bottom line
- Stroke prevention is decided from risk factors, separately from everything else.
- Rate control slows the heart rate without ending the fibrillation.
- Rhythm control tries to restore and hold a normal rhythm.
- Treating the drivers behind AFib is a fourth job and improves the results of the others.
- Successfully controlling rate or rhythm does not remove the need for anticoagulation in most at-risk people.
- Which patients benefit most from early rhythm control.
- How long anticoagulation should continue after successful ablation.
- How best to combine lifestyle treatment with procedures.
The story, step by step
- 1. Job one ()
- 2. Job two ()
- 3. Job three ()
- 4. Job four ()
- 5. How they fit ()
What the evidence labels mean
Preventing stroke
What happens
The decision with the biggest consequence.
What the research shows
- This is assessed from risk factors rather than symptoms, using a score as a starting point. The factors are age, prior stroke or TIA, high blood pressure, heart failure, diabetes, vascular disease and sex.
- For most people with meaningful risk, an oral anticoagulant is advised. A direct oral anticoagulant is first-line for most; warfarin is right in specific situations.
- Bleeding risk is assessed alongside it, but bleeding risk factors are mostly a reason to correct what is correctable rather than to withhold treatment.
- Aspirin is not an adequate substitute for people who need anticoagulation.
- For people who genuinely cannot take anticoagulants, a left atrial appendage closure device is an option in some centres.
- This decision is revisited over time, because risk rises with age even if nothing else changes.
Why it matters
This is the part of the plan that most changes long-term outcomes, and the part where stopping on your own does the most harm.
What's still uncertain
- How to manage people at high risk of both stroke and bleeding.
- How closure devices compare with modern anticoagulants.
Read more
- MedlinePlus: Blood thinnersGovernment
- NHLBI: Atrial fibrillationGovernment
- American Heart Association: atrial fibrillationNonprofit
Next: Job two
Rate control
What happens
Slowing the pulse without fixing the rhythm.
What the research shows
- Rate control aims to keep the heart rate in a comfortable range while allowing the atria to carry on fibrillating.
- The usual first choices are beta-blockers, such as metoprolol or bisoprolol, or non-dihydropyridine calcium channel blockers, such as diltiazem or verapamil.
- Digoxin is sometimes added, particularly in people who are less active or who have heart failure, and is used with care because the safe dose range is narrow.
- Calcium channel blockers of this type are generally avoided in significant heart failure with reduced pumping function.
- A lenient resting target, often under about 110 beats a minute, is acceptable for many people; a tighter target is used if symptoms persist.
- If medicines cannot control the rate and symptoms remain, AV node ablation with a pacemaker is a last-resort option.
Why it matters
Rate control is often enough on its own, and for many people it is the simpler and better-tolerated half of the rhythm question.
What's still uncertain
- What the optimal resting rate target is.
- Which patients do better with tight versus lenient control.
Read more
- NHLBI: Atrial fibrillationGovernment
- MedlinePlus: ArrhythmiaGovernment
- American Heart Association: atrial fibrillationNonprofit
Next: Job three
Rhythm control
What happens
Trying to restore normal rhythm.
What the research shows
- Rhythm control aims to get the heart back into sinus rhythm and keep it there, using antiarrhythmic drugs, cardioversion, ablation, or a combination.
- It is chosen mainly for symptoms that persist despite rate control, for younger people, for those with a shorter history of AFib, and where heart failure may be driven by the rhythm.
- Antiarrhythmic drugs include flecainide, propafenone, sotalol, dofetilide, dronedarone and amiodarone. Each has specific restrictions, and the choice depends on the rest of the heart.
- Amiodarone is the most effective but has the broadest long-term side-effect profile, affecting thyroid, lungs, liver, eyes and skin, so it is reserved and monitored.
- Flecainide and propafenone are avoided in people with significant coronary or structural heart disease.
- Evidence from recent trials suggests that starting rhythm control early after diagnosis may improve outcomes in selected people, which has shifted practice somewhat.
Why it matters
The historic view that rate and rhythm control were equivalent has been nuanced by newer trials, particularly for people diagnosed recently.
What's still uncertain
- Which patients benefit from early rhythm control.
- How ablation compares with drugs as a first treatment.
Read more
- NHLBI: Atrial fibrillationGovernment
- American Heart Association: atrial fibrillationNonprofit
- MedlinePlus: ArrhythmiaGovernment
Next: Job four
Treating what drives it
What happens
The part that improves everything else.
What the research shows
- Blood pressure control reduces atrial stretch and is the single most common driver to address.
- Treating obstructive sleep apnea is associated with fewer episodes and better results from cardioversion and ablation.
- Weight loss in people with obesity reduces AFib burden and improves the chance that rhythm treatments hold.
- Reducing or stopping alcohol has been shown in trial evidence to reduce episode frequency.
- An overactive thyroid is corrected, and diabetes and kidney disease are managed.
- This work is often presented as lifestyle advice and treated as optional. It is better understood as treatment that changes how well the rest of the plan works.
Why it matters
Procedures and medicines perform better in a heart whose drivers have been dealt with, which is why this is listed as a job rather than a footnote.
What's still uncertain
- How much progression can be prevented.
- Which combination of interventions gives the biggest effect.
Read more
- American Heart Association: atrial fibrillationNonprofit
- NHLBI: Sleep apneaGovernment
- NHLBI: High blood pressureGovernment
Next: How they fit
Reading your own plan
What happens
Knowing which medicine does which job.
What the research shows
- A typical plan has an anticoagulant for stroke prevention, a rate-slowing medicine, and sometimes an antiarrhythmic, plus treatment for blood pressure and other conditions.
- They are not interchangeable. A beta-blocker does nothing for clotting; an anticoagulant does nothing for the rate.
- A common and dangerous misunderstanding is assuming that a normal pulse or the absence of symptoms means the anticoagulant is no longer needed.
- Another is assuming a successful ablation ends the need for anticoagulation. For many people it does not, and that decision belongs to the clinician who knows the risk profile.
- It is worth being able to say, for each medicine you take, which of the jobs it does. Ask if you are not sure.
- Any change to an anticoagulant, including pausing it for dental work or surgery, should be planned with the prescriber.
Why it matters
Knowing which job each tablet does makes the plan easier to stick to and makes a dangerous substitution less likely.
What's still uncertain
- How best to support adherence over decades.
- How to simplify complex regimens safely.
Read more
- MedlinePlus: Blood thinnersGovernment
- NHLBI: Atrial fibrillationGovernment
- MedlinePlus: Atrial fibrillationGovernment